ABBVIE INC. $3,000,000,000 1.800% Notes due 2018 $3,750,000,000 2.500% Notes due 2020 $1,000,000,000 3.200% Notes due 2022 $3,750,000,000 3.600% Notes due 2025 $2,500,000,000 4.500% Notes due 2035 $2,700,000,000 4.700% Notes due 2045 UNDERWRITING...Underwriting Agreement • May 7th, 2015 • AbbVie Inc. • Pharmaceutical preparations • New York
AbbVie Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Barclays Capital Inc. and Deutsche Bank Securities Inc. (together, the “Representatives”) and the other several underwriters named in Schedule II hereto (together with the Representatives, the “Underwriters”) pursuant to this Underwriting Agreement (this “Agreement”) the principal amount of its debt securities identified in Schedule I hereto (the “Securities”), to be issued pursuant to the indenture dated as of November 8, 2012 (the “Base Indenture”) between the Company and U.S. Bank National Association, as Trustee (the “Trustee”), as supplemented by the Supplemental Indenture No. 1 dated as of November 8, 2012 (“Supplemental Indenture No. 1”) among the Company and the Trustee and the Supplemental Indenture No. 2 dated as of May 14, 2015 among the Company and the Trustee (the “Supplemental Indenture No. 2,” and together with t
